Belzutifan
PT2977 is a potential treatment for clear cell renal cell carcinoma (ccRCC) . PT2977 is an orally active and selective HIF-2α inhibitor (IC50: 9 nM) . PT2977, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. (In Vitro) :PT2977 effectively and dose-dependently decreased mRNA levels of human cyclin D1, a target gene regulated by HIF-2α. PT2977 reduced EPO expression in a rapid and dose-dependent manner.
Product Specifications
CAS Number
1672668-24-4
Product Name Alternative
MK-6482 | PT2977
Purity
>98% (HPLC)
Solubility
In Vitro: Acetone : 50 mg/mL (130.43 mM)
Smiles
CS (=O) (=O) c1ccc (Oc2cc (F) cc (c2) C#N) c2[C@@H] (F) [C@@H] (F) [C@@H] (O) c12
Molecular Formula
C17H12F3NO4S
Molecular Weight
383.34
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
M2825-14F-ML750 100 µL
MDR1 (P-Glycoprotein, Pgp170, MRP1, Multi Drug Resistance Associated Protein, ABCB1, ATP-binding cassette, sub-family B (MDR/TAP), member 1, ABC20, CD243, CD243 antigen, CLCS, GP170) (MaxLight 750) discontinued
Sign In for Pricing
View Details 
